• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

BioTime Inc.

economics regenerative medicine stemells tissue engineering regmed

  • Please log in to reply
777 replies to this topic

#751 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 30 November 2017 - 12:00 PM

Program to Be Presented at IFATS Conference
Business Wire (press release) - 22 minutes ago
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal ...

View the full article

#752 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 04 December 2017 - 12:00 PM

AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on ...
Business Wire (press release) - 8 hours ago
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX) announced today that Chief Executive Officer Michael D. West, Ph.

View the full article

#753 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 02 January 2018 - 12:00 PM

BioTime (BTX) Publishes Study on Identification of Genes Implicated in Tissue ...
StreetInsider.com - 19 hours ago
AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE: BTX), today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging.
BioTime up 6% on study identifying genes related to tissue regeneration - Seeking Alpha

View the full article

sponsored ad

  • Advert

#754 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 05 January 2018 - 09:22 PM

AgeX Therapeutics to Present at Biotech Showcase Annual Conference
Business Wire (press release) - 8 hours ago
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases.

View the full article

#755 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 08 January 2018 - 10:18 PM

BioTime Inc. (BTX) Soars 9.16% on January 08
Equities.com - 13 hours ago
BioTime Inc. (BTX) had a good day on the market for Monday January 08 as shares jumped 9.16% to close at $2.74. About 1.12 million shares traded hands on 3,822 trades for the day, compared with an average daily volume of 380,675 shares out of a total ...
Which Way is The Street Betting BioTime, Inc. (:BTX) Will Go? - Midway Monitor

View the full article

#756 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 15 January 2018 - 09:22 PM

Digging into the Technicals On BioTime, Inc. (AMEX:BTX)
Berry Recorder - 14 hours ago
Here we will take a look at several key ratios for BioTime, Inc. (AMEX:BTX), starting with the Book to Market (BTM) ratio.

View the full article

#757 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 17 January 2018 - 12:00 PM

BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent ...
Business Wire (press release) - 17 hours ago
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the issuance of 41 new patents over the past 12 ...

View the full article

#758 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 18 January 2018 - 12:00 PM

AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell ...
Business Wire (press release) - 11 hours ago
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that AgeX will present in a Plenary session, “Stem Cell Innovations That Will Change the World - Part 2,” at the World Stem ...

View the full article

#759 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 29 January 2018 - 12:00 PM

Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
Business Wire (press release) - 6 hours ago
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal ...

View the full article

#760 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 30 January 2018 - 08:26 PM

Unusual Activity Spotted in Celldex Therapeutics (CLDX) and Biotime Inc (BTX)
Concord Register - 8 hours ago
Needle moving action has been spotted in Celldex Therapeutics (CLDX) as shares are moving today on volatility -1.40% or -0.04 from the open.

View the full article

#761 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 31 January 2018 - 04:30 PM

What do Insider Trends Have to Say About BioTime, Inc. (BTX)?
StockNewsGazette - 23 hours ago
Recent insider trends for BioTime, Inc. (NYSE:BTX) have caught the attention of investors. Analysts study insider data to get a sense of sense of what key shareholders think about the outlook for a particular stock.

View the full article

#762 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 02 February 2018 - 03:10 PM

Adding Up the Valuation on BioTime, Inc. (AMEX:BTX)
Concord Register - 12 hours ago
The EBITDA Yield for BioTime, Inc. (AMEX:BTX) is -0.112955. The Earnings to Price yield of BioTime, Inc. (AMEX:BTX) is 0.135863. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the ...

View the full article

#763 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 07 February 2018 - 12:00 PM

BioTime to Participate at the BIO CEO and Investor Conference in New York ...
Business Wire (press release) - Feb 7, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer of ...
BioTime (NYSEAMERICAN:BTX) Stock Rating Lowered by Zacks Investment Research - The Lincolnian Online

View the full article

#764 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 11 February 2018 - 09:11 AM

Schwab Charles Investment Management Inc. Sells 57700 Shares of BioTime, Inc ...
Dispatch Tribunal - Feb 11, 2018
Schwab Charles Investment Management Inc. cut its position in BioTime, Inc. (NYSEAMERICAN:BTX) by 35.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
What's Transpiring For Shares of Biotime Inc (BTX) - Pearson Press

View the full article

#765 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 21 February 2018 - 04:30 PM

Granite Point Capital Management LP Purchases 185000 Shares of BioTime, Inc. (BTX)
The Lincolnian Online - 3 hours ago
BioTime logo Granite Point Capital Management L.P. grew its stake in shares of BioTime, Inc. (NYSEAMERICAN:BTX) by 415.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
Near-Term, Can This Stock Move the Needle: BioTime, Inc. (:BTX) - Collins Courier
What Kind of Picture Are the Technicals Painting For Biotime Inc (BTX)? - Jonesboro Recorder

View the full article

#766 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 22 February 2018 - 03:07 PM

Overall Technical picture of BioTime, Inc. (BTX)
Stocks Gallery - 13 hours ago
Shares of BioTime, Inc. (BTX) moved 2.72% in the recent trading day. Last trading transaction put the stock price at $2.64.

View the full article

#767 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 22 February 2018 - 12:00 PM

BioTime Appoints Cavan Redmond to Its Board of Directors
Business Wire (press release) - 16 hours ago
I am excited to join the BioTime board to help guide the leadership team during this transformational period in the company's evolution,” said Cavan Redmond.

View the full article

#768 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 07 February 2018 - 05:15 PM

A Look at the Health of BioTime, Inc. (AMEX:BTX)
Danvers Record - Feb 7, 2018
Taking a look at some historical volatility numbers on shares of BioTime, Inc. (AMEX:BTX), we can see that the 12 month volatility is presently 42.663000.

View the full article

#769 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 February 2018 - 12:56 PM

BioTime to Present at the Raymond James 39th Annual Institutional Investor ...
Markets Insider - 3 hours ago
BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at ...

View the full article

#770 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 28 February 2018 - 06:56 AM

BioTime's Dry AMD Product OpRegen: A Look At Trial Data
Seeking Alpha - 9 hours ago
This article will look at OpRegen, BioTime's dry AMD product candidate; we will follow through with a valuation next month.
BioTime, Inc. (BTX) Sees Significant Increase in Short Interest - The Ledger Gazette

View the full article

#771 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 01 March 2018 - 12:56 PM

AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in ...
Business Wire (press release) - Mar 1, 2018
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases.

View the full article

#772 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 07 March 2018 - 12:56 PM

BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen ...
Markets Insider - 19 hours ago
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ...

View the full article

#773 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 27 March 2018 - 10:52 AM

BioTime Announces Cash Sale of Ascendance Biotechnology
Business Wire (press release) - 13 hours ago
BioTime's lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of dry age-related macular degeneration, the leading cause of ...
BioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance ... - StreetInsider.com

View the full article

#774 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 22 April 2018 - 10:30 AM

Lapides Asset Management Upped Holding in Tile Shop Holdings (TTS) by $407700 ...
BZ Weekly - 20 hours ago
Neal C. Bradsher increased its stake in Biotime Inc (BTX) by 9.87% based on its latest 2017Q4 regulatory filing with the SEC.

View the full article

#775 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 23 April 2018 - 10:52 AM

Global Cell Therapy Processing Market Anticipated To Reach $5.0 billion in ...
Medgadget (blog) - 8 hours ago
WiseGuyReports have announced the addition of a new report titled “Cell Therapy Processing: Global Markets and Technologies”. Summary.
Global Human Embryonic Stem Cells Market Report 2017 to 2024 | Analysis, Size ... - Pharmaceuticals News

View the full article

#776 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 26 April 2018 - 10:52 AM

BioTime to Announce First Quarter 2018 Results on May 10, 2018
Business Wire (press release) - Apr 26, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10 ...

View the full article

#777 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 02 May 2018 - 10:52 AM

AgeX Announces NIH Grant Award
Markets Insider - 13 hours ago
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced the award of a grant of approximately $386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH).

View the full article

#778 ImmInst

  • Admin, Director robot
  • 2,350 posts
  • 72

Posted 01 May 2018 - 12:00 PM

BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
Markets Insider - May 1, 2018
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of its lead programs, OpRegen® for dry-AMD, was presented at the Association for Research in ...

View the full article





Also tagged with one or more of these keywords: economics, regenerative medicine, stemells, tissue engineering, regmed

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users